To evaluate pharmacokinetics, safety and efficacy of SNUBH-NM-333(18F), a new diagnostic radiopharmaceutical for PET imaging of amyloid plaques, in Alzheimer's disease patients and healthy volunteers.
The investigators will perform whole-body and brain kinetic modeling of SNUBH-NM-333(18F) and optimize the image acquisition procedure. Five young healthy subjects will be participated in Whole-body positron emission tomography /computed tomographic (PET/CT) scans from the midfemoral position to the head after approximately 5-10 mCi of SNUBH-NM-333(18F) injection. For brain PET/CT amyloid imaging, another five young healthy subjects will be scanned dynamically during windows of 0-180 min after injection of SNUBH-NM-333(18F), with arterial sampling. The investigators will compare different analysis methods of compartmental modeling and standardized uptake value ratios and determine the optimal acquisition window. And then 10 AD patients and 10 elderly healthy controls will also be participated in brain amyloid imaging to compare SNUBH-NM-333(18F) brain retention in AD patients versus healthy elderly.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
5-10 mCi
Seoul National University Hospital
Seoul, South Korea
Distribution volume ratio (DVR)
DVR = Distribution volume of region of interest/Distribution volume of reference region
Time frame: Whole-body positron emission tomography /computed tomographic (PET/CT) scans will be performed within 30 days after screening.
Standardized uptake value ratio (SUVr)
Time frame: Whole-body positron emission tomography /computed tomographic (PET/CT) scans will be performed within 30 days after screening.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.